LRRK2 p.Gly2019Ser帕金森病发病年龄跨祖先与国家的差异
本研究纳入922名无关的LRRK2 p.Gly2019Ser变异携带者,采用Cox比例风险模型分析不同祖先和国家间帕金森病累积发病率的差异。结果显示北非祖先发病年龄较欧洲祖先早5年,而德系犹太人祖先较欧洲祖先晚5年;以色列和突尼斯患者较美国患者发病年龄分别早5年和10年。遗传祖先和国家来源与LRRK2-PD发病年龄相关,提示遗传与环境因素共同影响。
要点
- 北非祖先LRRK2-PD发病年龄较欧洲祖先早5年(HR=1.48)。
- 德系犹太人祖先发病年龄较欧洲祖先晚5年(HR=0.61)。
- 以色列和突尼斯患者较美国患者发病年龄分别早5年和10年。
核心结论
- 遗传祖先和国家来源与LRRK2 p.Gly2019Ser相关帕金森病的发病年龄相关,提示遗传和环境因素均可能影响发病年龄。
研究设计与样本
- 研究纳入922名无关的p.Gly2019Ser变异携带者( affected=762,unaffected=160),来自全球帕金森遗传学项目(GP2)及以色列德系犹太人和突尼斯阿拉伯-柏柏尔人群队列,采用Cox比例风险模型分析,所有分析均校正生物学性别,为探索性分析。
主要发现
- 北非祖先LRRK2-PD中位发病年龄较欧洲祖先早5年(HR=1.48,95%CI=1.18-1.86,p=7.0×10^-4)。
- 德系犹太人祖先中位发病年龄较欧洲祖先晚5年(HR=0.61,95%CI=0.50-0.75,p=4.0×10^-6)。
- 以色列患者较美国患者中位发病年龄早5年(HR=1.59,95%CI=1.30-1.39,p=4.0×10^-6)。
- 突尼斯患者较美国患者中位发病年龄早10年(HR=2.57,95%CI=2.16-3.06,P<2.0×10^-16)。
- 仅分析德系犹太人背景个体时,以色列患者仍较美国患者发病年龄早(HR=1.82,95%CI=1.48-2.24,p=1.5×10^-8);仅分析美国患者时,德系犹太人祖先仍较欧洲祖先发病年龄晚(HR=0.51,95%CI=0.39-0.67,p=1.3×10^-6)。
临床怎么用
- 在遗传咨询和临床评估中,应考虑LRRK2 p.Gly2019Ser携带者的遗传祖先和国家来源对发病年龄的潜在影响。
局限性
- 研究为探索性分析,未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of this study was to elucidate differences in the cumulative incidence of Leucine-rich repeat kinase 2 (LRRK2) p.Gly2019Ser-related Parkinson's disease (PD; LRRK2-PD) between ancestries and countries. METHODS: We included 922 unrelated p.Gly2019Ser variant carriers (affected = 762 and unaffected = 160) from the Global Parkinson's Genetics Program (GP2) in addition to cohorts recruited from the Israeli Ashkenazi Jewish and Tunisian Arab-Berber population. Cox proportional hazard models were applied to examine differences in cumulative incidence across ancestry groups and countries. All analyses were adjusted for biological sex and were exploratory. RESULTS: The median age at onset (AAO) of LRRK2-PD was 5 years younger in the North African (hazard ratio [HR] = 1.48, 95% confidence interval [CI] = 1.18-1.86, p = 7.0 × 10-4) compared with the European ancestry group. In contrast, the median AAO was 5 years older in the Ashkenazi Jewish (HR = 0.61, 95% CI = 0.50-0.75, p = 4.0 × 10-6) compared with the European ancestry group. Additionally, patients from Israel (HR = 1.59, 95% CI = 1.30-1.39, p = 4.0 × 10-6) and Tunisia (HR = 2.57, 95% CI: 2.16-3.06, P < 2.0 × 10-16) had a median 5-year and 10-year younger AAO compared with patients from the United States, respectively. Last, when focusing only on individuals with an Ashkenazi Jewish background, patients from Israel still had a younger AAO than those from the United States (HR = 1.82, 95% CI = 1.48-2.24, p = 1.5 × 10-8). Analogously, assessing only patients from the United States, the Ashkenazi Jewish ancestry group still had an older AAO than the European ancestry group (HR = 0.51, 95% CI = 0.39-0.67, p = 1.3 × 10-6). INTERPRETATION: Our results provide evidence that a person's genetic ancestry and country of origin are associated with the AAO of LRRK2-PD. This highlights the potential impact of both genetic and environmental factors on LRRK2-PD AAO. ANN NEUROL 2026;99:1394-1404.
引用
- Lüth T, Laabs BH, Sendel S, et al. The Age at Onset of LRRK2 p.Gly2019Ser Parkinson's Disease Across Ancestries and Countries of Origin. Ann Neurol. 2026. PMID: 41735653. doi:10.1002/ana.78181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。